​

AN2 Therapeutics (ANTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ANTX Stock Forecast

AN2 Therapeutics (ANTX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $2.00, with a high of $2.00 and a low of $2.00. This represents a 48.15% increase from the last price of $1.35.

- $5 $10 $15 $20 $25 High: $2 Avg: $2 Low: $2 Last Closed Price: $1.35

ANTX Stock Rating

AN2 Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 3 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 3 5 Strong Sell Sell Hold Buy Strong Buy

ANTX Price Target Upside V Benchmarks

TypeNameUpside
StockAN2 Therapeutics48.15%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$2.00
Last Closing Price$1.35$1.35$1.35
Upside/Downside--48.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 251-1--2
Sep, 251-1--2
Aug, 251-1--2
Jul, 251-11-3
Jun, 251-11-3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 05, 2025Roy BuchananJMP Securities$2.00$1.2066.67%48.15%
Jul 03, 2024Joseph SchwartzLeerink Partners$5.00$2.13134.74%270.37%
May 16, 2024Liisa BaykoEvercore ISI$2.00$2.27-11.89%48.15%
Apr 02, 2024Roy BuchananJMP Securities$6.00$3.7659.57%344.44%
Nov 14, 2022Leerink Partners$25.00$14.8768.12%1751.85%
Apr 19, 2022Evercore ISI$25.00$14.0078.57%1751.85%
Apr 19, 2022Oppenheimer$22.00$14.7249.46%1529.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 05, 2025CitigroupOutperformOutperformhold
Aug 09, 2024Evercore ISIUnderperformdowngrade
Jul 03, 2024Leerink PartnersMarket PerformOutperformupgrade
Apr 02, 2024JMP SecuritiesOutperformupgrade
Feb 13, 2024Leerink PartnersMarket Performdowngrade
Nov 14, 2022SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.74-----
Avg Forecast$-2.98$-1.72$-1.14$-1.23$-1.16$-1.22
High Forecast$-2.92$-1.70$-0.98$-1.12$-1.16$-1.22
Low Forecast$-3.08$-1.73$-1.22$-1.29$-1.16$-1.22
Surprise %-8.05%-----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$33.20M$72.70M$217.00M$389.90M
High Forecast--$33.20M$72.70M$217.00M$389.90M
Low Forecast--$33.20M$72.70M$217.00M$389.90M
Surprise %------

Net Income Forecast

$-75M $-64M $-53M $-42M $-31M $-20M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.73M-----
Avg Forecast$-70.71M$-40.57M$-26.02M$-28.48M$-27.38M$-28.79M
High Forecast$-68.82M$-40.21M$-23.22M$-26.54M$-27.26M$-28.79M
Low Forecast$-72.60M$-40.93M$-28.82M$-30.41M$-27.49M$-28.79M
Surprise %-8.45%-----

ANTX Forecast FAQ

Is AN2 Therapeutics stock a buy?

AN2 Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AN2 Therapeutics is a favorable investment for most analysts.

What is AN2 Therapeutics's price target?

AN2 Therapeutics's price target, set by 8 Wall Street analysts, averages $2 over the next 12 months. The price target range spans from $2 at the low end to $2 at the high end, suggesting a potential 48.15% change from the previous closing price of $1.35.

How does AN2 Therapeutics stock forecast compare to its benchmarks?

AN2 Therapeutics's stock forecast shows a 48.15% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for AN2 Therapeutics over the past three months?

  • October 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is AN2 Therapeutics’s EPS forecast?

AN2 Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.72, marking a -37.23% decrease from the reported $-2.74 in 2023. Estimates for the following years are $-1.14 in 2025, $-1.23 in 2026, $-1.16 in 2027, and $-1.22 in 2028.

What is AN2 Therapeutics’s revenue forecast?

AN2 Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $33.2M, followed by $72.7M for 2026, $217M for 2027, and $389.9M for 2028.

What is AN2 Therapeutics’s net income forecast?

AN2 Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-40.567M, representing a -37.33% decrease from the reported $-64.732M in 2023. Projections indicate $-26.017M in 2025, $-28.475M in 2026, $-27.376M in 2027, and $-28.792M in 2028.